ReNeuron to manufacture exosomes for gene therapies

By The Science Advisory Board staff writers

June 25, 2020 -- ReNeuron signed a research evaluation agreement with a U.S. biotechnology company for the use of its proprietary exosomes for the delivery of novel gene silencing therapies.

The research will focus on ReNeuron's human neural stem cell-derived exosomes for the delivery of the biotech company's neuroscience therapeutic candidates. ReNeuron will be responsible for manufacturing the exosomes and loading them with the gene-silencing sequences, after which the biotech company will evaluate the loaded exosomes. Upon successful preclinical evaluation, the companies will jointly own the novel therapeutic candidate for future development.

ReNeuron's line of human neural stem cell-derived exosomes are produced by a fully qualified, xeno-free, scalable process, according to the firm. The exosomes can be loaded with a diverse range of therapeutic molecules such as small interfering RNA, messenger RNA, microRNA, CRISPR/Cas9, antibodies, peptides, and other small molecules.

New mechanism elucidated for essential molecule-sorting organelle
A new study published in Nature Communications on November 15 suggests a new mechanism by which vesicles are transported out of the Golgi apparatus...
New targeted therapy for lung cancer using precious metals as Trojan exosomes
Researchers at the University of Edinburgh and the Universidad de Zaragoza in Spain present a novel therapeutic approach to treating cancer on September...

Copyright © 2020 scienceboard.net


Conferences
Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter